title: Combined 3D-QSAR, molecular docking, and molecular dynamics study on piperazinyl-glutamate-pyridines/pyrimidines as potent P2Y12 antagonists for inhibition of platelet aggregation.
abstract: An unusually large data set of 397 piperazinyl-glutamate-pyridines/pyrimidines as potent orally bioavailable P2Y(12) antagonists for inhibition of platelet aggregation was studied for the first time based on the combination of three-dimensional quantitative structure-activity relationship (3D-QSAR), molecular docking, and molecular dynamics (MD) methods. The comparative molecular field analysis (CoMFA) and comparative molecular similarity index analysis (CoMSIA) studies have been performed with a training set of 317 compounds, estimating three superimposition methods. The best CoMFA and CoMSIA models, derived from superimposition I, shows leave-one-out cross-validation correlation coefficients (Q(2)) of 0.571 and 0.592 as well as the conventional correlation coefficients (R(2)(ncv)) of 0.814 and 0.834, respectively. In addition, the satisfactory results, based on the bootstrapping analysis and 10-fold cross-validation, further indicate the highly statistical significance of the optimal models. The external predictive abilities of these models were evaluated using a prediction set of 80 compounds, producing the predicted correlation coefficients (R(2)(pred)) of 0.664 and 0.668, respectively. The key amino acid residues were identified by molecular docking, and the stability and rationality of the derived molecular conformations were also validated by MD simulation. The good concordance between the docking results and CoMFA/CoMSIA contour maps provides helpful clues about the rational modification of molecules in order to design more potent P2Y(12) antagonists. We hope the developed models could provide some instructions for further synthesis of highly potent P2Y(12) antagonists.
authors.affiliation: Department of Materials Science and Chemical Engineering, Dalian University of Technology, Dalian, Liaoning 116023, China.
authors.forename: Ming
authors.initials: M
authors.lastname: Hao
authors.forename: Yan
authors.initials: Y
authors.lastname: Li
authors.forename: Yonghua
authors.initials: Y
authors.lastname: Wang
authors.forename: Yulian
authors.initials: Y
authors.lastname: Yan
authors.forename: Shuwei
authors.initials: S
authors.lastname: Zhang
authors.forename: Guohui
authors.initials: G
authors.lastname: Li
authors.forename: Ling
authors.initials: L
authors.lastname: Yang
mesh_terms: D001682:Biological Availability; D018698:Glutamic Acid / Q000737:chemistry*; D006573:Heterocyclic Compounds, 1-Ring / Q000737:chemistry*; D006801:Humans; D056004:Molecular Dynamics Simulation; D000077489:Piperazine; D010879:Piperazines / Q000737:chemistry; D010974:Platelet Aggregation / Q000187:drug effects*; D011487:Protein Conformation; D058921:Purinergic P2Y Receptor Antagonists / Q000737:chemistry / Q000378:metabolism / Q000493:pharmacokinetics / Q000494:pharmacology*; D011725:Pyridines / Q000737:chemistry; D011743:Pyrimidines / Q000737:chemistry; D021281:Quantitative Structure-Activity Relationship; D058925:Receptors, Purinergic P2Y12 / Q000737:chemistry / Q000378:metabolism*; D015203:Reproducibility of Results
chemical_list: D006573:Heterocyclic Compounds, 1-Ring; D010879:Piperazines; D058921:Purinergic P2Y Receptor Antagonists; D011725:Pyridines; D011743:Pyrimidines; D058925:Receptors, Purinergic P2Y12; D000077489:Piperazine; D018698:Glutamic Acid; C030986:pyrimidine; C023666:pyridine